Onilcamotide Fails to Reduce Risk of Progression in Prostate Cancer With Biochemical Recurrence

Retrieved on: 2022-06-16 19:42:35

Tags for this article:

Click the tags to see associated articles and topics

Onilcamotide Fails to Reduce Risk of Progression in Prostate Cancer With Biochemical Recurrence. View article details on hiswai:

Excerpt

... with prostate cancer and biochemical recurrence following curative-intent therapy, missing the primary end point of the phase 2b BRaVac trial.

Article found on: www.onclive.com